Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 23:8:39.
doi: 10.3389/fonc.2018.00039. eCollection 2018.

Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy

Affiliations
Review

Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy

Athanasios Blanas et al. Front Oncol. .

Erratum in

Abstract

Aberrant glycosylation of tumor cells is recognized as a universal hallmark of cancer pathogenesis. Overexpression of fucosylated epitopes, such as type I (H1, Lewisa, Lewisb, and sialyl Lewisa) and type II (H2, Lewisx, Lewisy, and sialyl Lewisx) Lewis antigens, frequently occurs on the cancer cell surface and is mainly attributed to upregulated expression of pertinent fucosyltransferases (FUTs). Nevertheless, the impact of fucose-containing moieties on tumor cell biology is not fully elucidated yet. Here, we review the relevance of tumor-overexpressed FUTs and their respective synthesized Lewis determinants in critical aspects associated with cancer progression, such as increased cell survival and proliferation, tissue invasion and metastasis, epithelial [corrected] to mesenchymal transition, endothelial and immune cell interaction, angiogenesis, multidrug resistance, and cancer stemness. Furthermore, we discuss the potential use of enhanced levels of fucosylation as glycan biomarkers for early prognosis, diagnosis, and disease monitoring in cancer patients.

Keywords: Lewis antigens; cancer; fucosylation; fucosyltransferases; glycosylation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cell-surface fucosylated antigens. Type I (H1, Lewisa, Lewisb, and sialyl Lewisa) and type II (H2, Lewisx, Lewisy, and sialyl Lewisx) Lewis antigens are terminal fucosylated carbohydrate motifs decorating cell surface glycoproteins or glycolipids. In the case of glycoproteins, N- and O-linked glycans containing Lewis antigens are covalently attached to the protein at Asparagine (Asn), or Serine and Threonine (Ser/Thr) residues, respectively. Expression of Lewis antigens is attributed to the expression of key enzymes, named fucosyltransferases (FUTs). The substrate specificity of different FUTs determines the site-specific transfer of fucose to oligosaccharides and the synthesis of the respective Lewis determinants.
Figure 2
Figure 2
Involvement of fucosylated antigens in different aspects of cancer progression. Due to genetic or epigenetic alterations, overexpression of certain fucosyltransferases (FUTs) by cancer cells leads to increased cell-surface expression of fucosylated Lewis antigens. Aberrant regulation of the fucosylation machinery in cancer cells is causally associated with the acquisition of various tumorigenic properties, such as increased cell survival and proliferation, epithelial to mesenchymal transition, metastasis, resistance to chemotherapy, and cancer stemness. In parallel, interaction of cancer cells overexpressing Lewis antigens with endothelial or immune cells bearing Lewis antigen-specific receptors might also play a critical role during cancer-induced angiogenesis and immunosuppression, respectively.

References

    1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell (2000) 100(1):57–70.10.1016/s0092-8674(00)81683-9 - DOI - PubMed
    1. Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646–74.10.1016/j.cell.2011.02.013 - DOI - PubMed
    1. Munkley J, Elliott DJ. Hallmarks of glycosylation in cancer. Oncotarget (2016) 7(23):35478–89.10.18632/oncotarget.8155 - DOI - PMC - PubMed
    1. Hakomori S, Kannagi R. Glycosphingolipids as tumor-associated and differentiation markers. J Natl Cancer Inst (1983) 71(2):231–51. - PubMed
    1. Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer (2015) 15(9):540–55.10.1038/nrc3982 - DOI - PubMed